Plant Doctor IPO disclosure split: distribution in filings, franchise support for merchants

What Happened

Plant Doctor, formally Beijing Plant Doctor Cosmetics Co., Ltd., recently updated its IPO prospectus and continued its push for the Shanghai Stock Exchange main board, according to the supplied brief.

The reported tension is simple: in IPO materials and inquiry responses, Plant Doctor characterizes the main offline network as distributor-operated authorized specialty stores. In merchant-facing materials, the brief says the company website uses franchise support language and describes operational help that covers much of a store's lifecycle.

The useful answer for readers is not that the model has already been legally classified. The supplied material does not show that. The useful answer is that the gap between the two descriptions is now the central disclosure question.

Why The Store Model Matters

As of the end of 2025, the brief says Plant Doctor had 4,268 offline chain stores. Of those, 480 were direct-operated terminal stores and 3,788 were authorized specialty stores opened by distributors.

Those stores reportedly use a unified Plant Doctor sign, unified brand image, and Plant Doctor-supplied products. The brief says this operating shape looks similar to common franchise models, which is why the distinction between distribution and franchise-style support matters for market interpretation.

Plant Doctor's response, as summarized in the brief, is that it does not charge franchise fees, management fees, or brand-use fees, and that its profit mainly comes from product sales to distributors. That explanation may distinguish the economics, but the merchant-facing franchise support language still leaves an evidence gap that Plant Doctor would need to explain more clearly.

Financial Context

The brief describes Plant Doctor as entering a slower-growth phase. In 2025, revenue was RMB 2.167 billion, up only 0.53% year on year, while net profit attributable to the parent was RMB 218 million, down by more than 10%.

The offline distribution channel remains the main revenue base. Distributor sales brought in RMB 1.402 billion in 2025, more than 60% of revenue, according to the brief.

The company is also trying to improve store efficiency. The brief says authorized distributor stores fell to 3,788 at the end of 2025, down 336 from 2023, as the company tightened single-store cost-effectiveness reviews and closed some lower-performing distributor stores through discussions with distributors.

Online Shift And Execution Checks

Plant Doctor is not only shrinking weak offline exposure. The brief says it is also using its store network to support instant retail and online repeat purchasing, including entry onto Meituan and JD platforms.

The Xiaozhi Mall is presented in the brief as a key online extension of offline stores. Consumers can scan a store or guide-specific QR code, bind to a corresponding store, and then choose store pickup, store inventory consumption, or direct shipment by Plant Doctor. The brief says Xiaozhi Mall generated RMB 183 million in 2025, close to 10% of revenue.

The execution question is whether Plant Doctor can balance online and offline pricing while turning store relationships into repeat online purchases. The brief suggests this could improve customer purchase frequency and lifetime value, but it does not prove that the strategy will succeed.

Evidence Limits

This article uses only the supplied event brief as factual material. It does not independently verify the prospectus, the website page, regulatory correspondence, store contracts, merchant interviews, or later updates after the event timestamp of July 14, 2026.

The brief supports a cautious conclusion: there is a reported inconsistency between regulatory-facing distribution language and merchant-facing franchise support language. It does not support a claim that regulators have rejected the IPO, that Plant Doctor violated disclosure rules, or that any investment outcome is likely.

The brief also includes market-risk language. This article is informational only and is not financial advice. Readers should treat IPO, equity, and crypto-market decisions as risk-bearing choices that require their own verification and judgment.

Practical Checks For Readers

Readers evaluating the story can check whether Plant Doctor later clarifies the economic substance of its authorized store model, including who controls store operations, who bears risk, whether any store-opening payments exist, and how profit is generated.

A second practical check is consistency of wording. If the same store network is described one way to regulators and another way to potential merchants, the useful follow-up is whether the company reconciles those terms in later public materials.

A third check is whether the online transition changes the revenue mix without creating channel conflict. The brief flags price balance between online and offline channels as a future challenge, so that is a concrete item to monitor rather than assume.

Bybit News Context

For Bybit news readers, this Plant Doctor IPO item is best treated as a governance and disclosure-monitoring story. It is not a crypto market signal and it does not say anything about Bybit registration, ranking, traffic, rewards, or trading outcomes.

Readers who already use Bybit-related market tools can place this kind of corporate news beside broader watchlists and risk notes. The supplied campaign destination is BYBIT official destination and the supplied code is 7nfg8123. Treat that as a navigation option only, not as a recommendation or promised result.